These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32204428)

  • 1. Delivery of siRNA to Ewing Sarcoma Tumor Xenografted on Mice, Using Hydrogenated Detonation Nanodiamonds: Treatment Efficacy and Tissue Distribution.
    Claveau S; Nehlig É; Garcia-Argote S; Feuillastre S; Pieters G; Girard HA; Arnault JC; Treussart F; Bertrand JR
    Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32204428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene.
    Bertrand JR; Pioche-Durieu C; Ayala J; Petit T; Girard HA; Malvy CP; Le Cam E; Treussart F; Arnault JC
    Biomaterials; 2015 Mar; 45():93-8. PubMed ID: 25662499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing subcellular-resolved organ distribution of cationic copolymer-functionalized fluorescent nanodiamonds for optimal delivery of active siRNA to a xenografted tumor in mice.
    Claveau S; Kindermann M; Papine A; Díaz-Riascos ZV; Délen X; Georges P; López-Alemany R; Tirado ÒM; Bertrand JR; Abasolo I; Cigler P; Treussart F
    Nanoscale; 2021 May; 13(20):9280-9292. PubMed ID: 33982741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the internalization pathway on the efficacy of siRNA delivery by cationic fluorescent nanodiamonds in the Ewing sarcoma cell model.
    Alhaddad A; Durieu C; Dantelle G; Le Cam E; Malvy C; Treussart F; Bertrand JR
    PLoS One; 2012; 7(12):e52207. PubMed ID: 23284935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells.
    Alhaddad A; Adam MP; Botsoa J; Dantelle G; Perruchas S; Gacoin T; Mansuy C; Lavielle S; Malvy C; Treussart F; Bertrand JR
    Small; 2011 Nov; 7(21):3087-95. PubMed ID: 21913326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.
    Toub N; Bertrand JR; Tamaddon A; Elhamess H; Hillaireau H; Maksimenko A; Maccario J; Malvy C; Fattal E; Couvreur P
    Pharm Res; 2006 May; 23(5):892-900. PubMed ID: 16715379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.
    Minas TZ; Han J; Javaheri T; Hong SH; Schlederer M; Saygideğer-Kont Y; Çelik H; Mueller KM; Temel I; Özdemirli M; Kovar H; Erkizan HV; Toretsky J; Kenner L; Moriggl R; Üren A
    Oncotarget; 2015 Nov; 6(35):37678-94. PubMed ID: 26462019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
    Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
    Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Osgood CL; Tantawy MN; Maloney N; Madaj ZB; Peck A; Boguslawski E; Jess J; Buck J; Winn ME; Manning HC; Grohar PJ
    Sci Rep; 2016 Sep; 6():33926. PubMed ID: 27671553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.
    Dallmayer M; Li J; Ohmura S; Alba Rubio R; Baldauf MC; Hölting TLB; Musa J; Knott MML; Stein S; Cidre-Aranaz F; Wehweck FS; Romero-Pérez L; Gerke JS; Orth MF; Marchetto A; Kirchner T; Bach H; Sannino G; Grünewald TGP
    Cell Death Dis; 2019 Feb; 10(2):116. PubMed ID: 30741933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adsorption of drugs on nanodiamond: toward development of a drug delivery platform.
    Mochalin VN; Pentecost A; Li XM; Neitzel I; Nelson M; Wei C; He T; Guo F; Gogotsi Y
    Mol Pharm; 2013 Oct; 10(10):3728-35. PubMed ID: 23941665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyamidoamine-Decorated Nanodiamonds as a Hybrid Gene Delivery Vector and siRNA Structural Characterization at the Charged Interfaces.
    Lim DG; Rajasekaran N; Lee D; Kim NA; Jung HS; Hong S; Shin YK; Kang E; Jeong SH
    ACS Appl Mater Interfaces; 2017 Sep; 9(37):31543-31556. PubMed ID: 28853284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.